RA Capital, a 10% Owner and Director, Makes Substantial $172M Post-IPO Investment in Hemab Therapeutics
COAG is trading near its 52-week low of $23.475 (5.9% above the low).
Summary
RA Capital Healthcare Fund LP, a 10% owner and director, significantly increased its stake in Hemab Therapeutics Holdings, Inc. with over $172 million in combined open market purchases and preferred stock conversions following the company's recent IPO.
Key Events · Ownership and Investor Activity · COAG
-
Significant Insider Investment
RA Capital Healthcare Fund LP, a 10% owner and director, acquired shares totaling over $172 million through a combination of open market purchases and preferred stock conversions.
-
Post-IPO Confidence
The transactions include open market purchases of common stock valued at over $52 million, with prices ranging from the IPO price of $18.00 up to $25.00 per share, demonstrating conviction above the initial offering price.
-
Timing After Upsized IPO
These transactions occurred between May 4-6, 2026, immediately following Hemab Therapeutics' recently completed upsized initial public offering, which was priced at $18.00 per share.
Analysis · COAG · Life Sciences
This Form 4 filing indicates a strong vote of confidence from RA Capital Healthcare Fund LP, a major institutional investor with board representation, in Hemab Therapeutics Holdings, Inc. The combined open market purchases and preferred stock conversions, totaling over $172 million, represent a substantial investment following the company's recent upsized IPO. The open market purchases, some made above the IPO price, suggest that RA Capital sees significant value in the company post-listing. This large insider buying activity from a key investor and director group could be interpreted positively by the market, signaling strong conviction in Hemab's future prospects.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COAG was trading at $24.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $23.48 to $32.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.